Mobile

A study to evaluate the safety and tolerability of ascending doses of UCART19 given as a single infusion in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) and to de...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-000296-24

A study to evaluate the safety and tolerability of ascending doses of UCART19 given as a single infusion in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukaemia (ALL) and to determine the maximum tolerated dose (MTD)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of several doses of UCART19 in patient with relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL) and to determine the maximum tolerated dose (MTD).

Critère d'inclusion

  • Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL)

Liens